Our Faculty

Prof. Dr. Lieven Annemans

Prof. Dr. Lieven Annemans has participated in more than 400 health economic evaluations in over 20 countries across a wide spectrum of therapeutic areas. He has also been involved as an expert in a large number of Health Technology Assessments (HTAs) and is actively involved in HTA on a European level.

Lieven has a unique profile: academic professor, past-president of ISPOR, author of Health economics for non-economists (Pelckmans Pro, 2018), trainer and consultant.

Highly respected for his vast international and cross-therapeutic experience, Lieven is a much sought-after advisor and educator to health policy makers and the innovative healthcare industry.

Gary Johnson

Gary is the Founder & Chairman of Inpharmation, Europe’s most respected pharma forecasting & pricing specialist consultancy, and the author of "Value Pricing for Market Access: Evidence-Based Pricing for Pharmaceuticals" and "Sales Forecasting for Pharmaceuticals: An Evidence Based Approach".

Gary and his team have been involved in the pricing and/or forecasting of around half of the new molecular entity launches over the past 5 years.

Dr. Nick Proctor

Dr. Nick Proctor is a senior consultant to the pharmaceutical industry for over 20 years, most recently as a Partner with Access Infinity. Over the past 15 years, he has led pricing, reimbursement and access projects for the majority of the world’s top pharmaceutical brands and manufacturers.

Nick has a strong background in pricing, evidence synthesis, health economics and outcomes research, as well as experience of working with payers in all major developed and emerging international health markets.

Maaike Addicks, MD

Maaike Addicks, MD is an independent Medical Affairs consultant with expertise in strategic Medical Affairs development, change management and Medical Affairs competency development.

She is a Board Member and currently Chair of the Medical Affairs Committee of the Dutch Association of Pharmaceutical Medicine (NVFG).

Maaike is a physician with over 15 years of on-the-job experience in Medical Affairs in mid-size and big pharma, in both headquarters and national affiliates, across a wide spectrum of therapeutic areas.

She has 10 years of experience in managing Medical Managers, Medical Advisors and MSLs, with both hands-on and strategic experience in Medical Affairs.

Ben Harbour

Ben Harbour is Managing Director UK with Across Health, Europe's leading consultancy specialised in omnichannel customer engagement strategies for life science organisations. 

Ben is a strategic advisor to pharma, biotech and medical device companies on multi-channel communication programmes at the corporate, regional and brand level. 

He has extensive international experience spanning the clinical, medical and commercial phases of product development across a wide range of therapeutic indications. 

Chris Toller

Chris Toller is a leading international consultant in pharmaceutical Medical Affairs who has worked with MA teams across the globe. 

Chris’ professional roles have included Managing Director at Choice Healthcare Solutions, Head of Strategy for the Choice Group, and Founder & MD of one of the UK’s first specialist medical communications agencies. Currently, he is Managing Partner at Havas Life Medicom UK. 

After his education as a physician, Chris built a career that has enabled him to work with Medical Affairs teams all over the world and in just about every therapy area. He has devised MA strategies and implemented programmes to support more than 50 medical brands on behalf of the world’s leading pharma companies. 

Dr. Patrik Frei

Dr. Patrik Frei is Founder & CEO of Venture Valuation, specialists in independent assessments and valuation of emerging high-growth companies in biotechnology and life sciences.

He is Europe’s top valuation expert of high-growth life science companies and author of Assessment and Valuation of High Growth Companies.

Patrik and his team carried out valuations for the Novartis Venture Fund.

He is the owner of Biotechgate, the global business development database for the life science industry.

Edouard Demeire

Edouard Demeire is Visiting Professor at CEDEP (INSEAD) and author of KICCASS PHARMA – Keep it Customer Centric, Agile & Strategically Simple In Pharma & Diagnostic Management (2020).

He has contributed to the design of Roche’s and Novartis’ brand planning processes and runs courses for marketing and non-marketing audiences worldwide.

Edouard developed business simulations and decision support tools for the health care industry and trained tens of thousands of executives worldwide on pharma marketing strategy since 1990.

Expert faculty member of:

Dr. Roger Cox

Dr. Roger Cox has 30 years of licensing experience encompassing both big and small pharma/biotech companies.

Currently Regional Advisor for UK and Europe with Plexus Ventures, Roger was formerly Executive Director with J&J’s Global Pharma BD Group where he negotiated over 50 commercial licence agreements.

Expert faculty member of:

Mark Tolboom

Mark Tolboom is partner at Vintura, a specialised consultancy firm for healthcare and life science companies.

He brings over 20 years of healthcare and life sciences management consulting experience. He has successfully guided global pharma companies in integrating VBHC into their operations and has demonstrated the added value it brings.  

David Scott

Formerly a pharma BusDev & Licensing executive, David Scott has worked as a Senior BD&L Consultant since 1996.

He has concluded numerous inward and outward licensing agreements for clients covering small molecules, biologicals and delivery technologies.

David is the author of Scrip’s best-selling report Practical Guide to Pharmaceutical Licensing.

Expert faculty member of:

Dr. Silvia Rohr

Dr. Silvia Rohr is Principal at Vintura, a specialised consultancy firm for healthcare and life science companies. 

She has spent the past eight years supporting teams in grasping the concept of VBHC and taking the first steps towards its implementation. She has been instrumental in (re-)defining the ambition and strategy for VBHC in pharmaceutical companies, as well as bringing these ambitions to fruition.

Dr. Carlos Velez

Dr. Carlos Velez is Founder and Managing Partner of Lacerta Bio, an international consultancy specialising in both in- and out-licensing of prescription and non-prescription product candidates and commercial products, across multiple therapeutic areas and markets.

Prior to that, Carlos built a 10+ years career in senior Business Development roles at Penwest Pharmaceuticals, Lantic Therapeutics Forest Labs, and Genencor (now Danisco).

Carlos has trained and consulted life science executives around the world on in- and out-licensing. 

Prof. Dr. Thomas Wilke

Prof. Dr. Thomas Wilke has 25+ years of experience in leading and conducting European and German RWE studies, including database studies, linked data studies, medical chart reviews and surveys.

In addition to being an academic researcher and author of numerous articles, Thomas is leading the University-affiliated institute IPAM and acts as senior scientist at GIPAM, a consultancy specialised on European RWE studies.

Jean-Sebastien Struyf

Jean-Sebastien Struyf is Senior Strategy Consultant with Across Health, Europe's leading consultancy specialised in omnichannel customer engagement strategies for life science organisations. 

Before joining Across Health, Jean-Sebastien led (directly and indirectly) extensive teams at leading pharmaceutical companies, such as Novartis and Bristol-Myers Squibb, in a range of commercial and strategic roles in Belgium & Europe and in direct cooperation with global HQs, in the areas of marketing, salesforce effectiveness, and multichannel customer engagement. 

At Across Health Jean-Sebastien has worked on countless multi-channel projects for leading pharmaceutical and medtech companies across various therapeutic areas. 

Expert faculty member of:

Aida Diaz-Agero

Aida Diaz-Agero is a Strategy Consultant at Across Health, Europe's leading consultancy specialised in omnichannel customer engagement strategies for life science organisations. 

Aida has extensive marketing and sales experience in the pharmaceutical industry in Europe. Having had responsibility over different teams with a strategic and a tactical approach, she focuses on developing and empowering its members to drive performance. 

She has participated in developing multiple launch readiness plans ensuring an omnichannel approach. Her experience has expanded across multiple therapeutic areas since she joined Across Health in 2023. 

Expert faculty member of:

Sam Johnson

As Board Director and Head of Research and Development, Sam leads the development of forecasting and pricing technologies at Inpharmation, Europe’s most respected pharma forecasting & pricing specialist consultancy.

Sam and the team at Inpharmation have been involved in the pricing and/or forecasting of around half of the new molecular entity launches over the past 5 years.

Kurt Arco

As an independent consultant, Kurt advises on commercial and launch excellence, drawing from his 20+ years of international experience within big and small pharma/biotech companies. 

Formerly, he was Global Launch Excellence Expert with Trilations, a strategic consultancy. 

Prior to that, Kurt led several major brand launches at MSD (Merck & Co), internationally and across several therapeutic areas. 

Jo Lopez

Jo Lopez is Practice Lead Early Commercialisation and Launch Excellence at Uptake, a global, value-driven independent healthcare consultancy focused on driving uptake across the pharma and biotech industry.

She is an international pharmaceutical leader with 20+ years of experience, specialising in launch excellence and early commercialisation.

Before joining Uptake, Jo held senior global launch roles at GSK and local commercial and market access roles at Roche. 

Mark Watson

Mark Watson is Senior Strategy Consultant with Across Health, Europe's leading consultancy specialised in omnichannel customer engagement strategies for life science organisations. 

He is a healthcare industry leader in the omnichannel space with specific expertise in digital transformation, customer-centric strategies and impact measurement. 

Mark has supported numerous cross-functional launch teams of leading pharma companies at both HQ and affiliate level.